Some human studies with intervention lengths of 4–12 weeks in patients with type 2 diabetes mellitus or hypertension have reported improvements in glycosylated haemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial glucose, insulin, and C-peptide20, total cholesterol21, LDL cholesterol22, blood pressure21 for individuals with essential11 or nonresponsive23 hypertension, whilst other studies have reported no changes in glucose parameters24, 25, and unchanged LDL cholesterol25. The gene discussed is INS; the disease is Hypertension.